左束分支区域起搏与常规心脏同步疗法的安全性和有效性在心力衰竭中 (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名:Jacqueline Beaulieu
- 电话号码:1-800-227-3422
- 邮箱:jacqueline.beaulieu@bsci.com
学习地点
-
-
Alabama
-
Huntsville、Alabama、美国、35801
- 招聘中
- Heart Center Research, LLC
-
接触:
- John Jennings, Dr.
-
首席研究员:
- John Jennings, Dr.
-
Mobile、Alabama、美国、36608
- 招聘中
- Mobile Infirmary Medical Center
-
接触:
- Ernest Matthew Quin, Dr.
-
首席研究员:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic Phoenix
-
接触:
- Mayank Sardana, MD
-
首席研究员:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro、Arkansas、美国、72401
- 招聘中
- Arrhythmia Research Group
-
接触:
- Devi Nair, Dr.
-
首席研究员:
- Devi Nair, Dr.
-
-
California
-
La Jolla、California、美国、92037
- 招聘中
- Scripps Memorial Hospital
-
接触:
- Nicolas Olson, MD
-
首席研究员:
- Nicolas Olson, MD
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars Sinai Medical Center
-
首席研究员:
- Ashkan Ehdaie, MD
-
接触:
- Ashkan Ehdaie, MD
-
Oakland、California、美国、94609
- 招聘中
- Alta Bates Summit Medical Center
-
接触:
- Rajan Shah, Dr.
-
首席研究员:
- Rajan Shah, Dr.
-
Santa Monica、California、美国、90404
- 招聘中
- Pacific Heart Institute
-
接触:
- Stephen Tang, MD
-
首席研究员:
- Stephan Tang, MD
-
Torrance、California、美国、90505
- 招聘中
- Torrance Medical Center
-
首席研究员:
- Gene Kim, MD
-
接触:
- Gene Kim, MD
-
Ventura、California、美国、93003
- 招聘中
- Cardiology Associates Medical Group, Inc.
-
接触:
- Jonathan Dukes, Dr.
-
首席研究员:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- Washington Hospital Center
-
接触:
- Cyrus Hadadi, MD
-
首席研究员:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota、Florida、美国、34239
- 招聘中
- Sarasota Memorial Hospital
-
接触:
- Antonio Moretta, Dr.
-
首席研究员:
- Antonio Moretta, Dr.
-
Tampa、Florida、美国、33613
- 招聘中
- AdventHealth Tampa
-
首席研究员:
- Kenneth Yamamura, MD
-
接触:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta、Georgia、美国、30309
- 招聘中
- Piedmont Hospital
-
接触:
- Kavita Krishnasamy, MD
-
首席研究员:
- Kavita Krishnasamy, MD
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University Hospital
-
接触:
- Anand Shah, MD
-
首席研究员:
- Anand Shah, MD
-
-
Idaho
-
Meridian、Idaho、美国、83642
- 招聘中
- St. Luke's Idaho Cardiology Associates
-
接触:
- Justice Oranefo, MD
-
首席研究员:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale、Illinois、美国、60521
- 招聘中
- University of Chicago
-
接触:
- Shrinath Yeshwant, MD
-
首席研究员:
- Shrinath Yeshwant, MD
-
Naperville、Illinois、美国、60540
- 撤销
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis、Indiana、美国、46250
- 招聘中
- Community Heart and Vascular Hospital
-
接触:
- Krishna Malineni, MD
-
首席研究员:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa Hospitals and Clinics
-
首席研究员:
- Paari Dominic, MD
-
接触:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville、Kentucky、美国、40207
- 招聘中
- Baptist Hospital East Louisville
-
首席研究员:
- Kevin Parrott, MD
-
接触:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River、Massachusetts、美国、02720
- 招聘中
- Southcoast Physicians Group
-
接触:
- Arnoldas Giedrimas, MD
-
首席研究员:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Hospitals
-
首席研究员:
- Thomas Crawford, MD
-
接触:
- Thomas Crawford, MD
-
Grand Rapids、Michigan、美国、49525
- 招聘中
- Corewell Health
-
接触:
- Jawad Wassim, MD
-
首席研究员:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth、Minnesota、美国、55805
- 撤销
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud、Minnesota、美国、56303
- 撤销
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown、New Jersey、美国、07932
- 招聘中
- Morristown Medical Center
-
接触:
- Michael Katz, MD
-
首席研究员:
- Michael Katz, MD
-
-
New York
-
Albany、New York、美国、12211
- 招聘中
- Capital Cardiology Associates
-
接触:
- Rizwan Alimohammad, MD
-
首席研究员:
- Rizwan Alimohammad, MD
-
Flushing、New York、美国、11355
- 招聘中
- New York Hospital Queens
-
接触:
- Seth Goldbarg, Dr.
-
首席研究员:
- Seth Goldbarg, Dr.
-
New York、New York、美国、10021
- 招聘中
- Weill Cornell Medical University
-
接触:
- Jim Cheung, Dr.
-
首席研究员:
- Jim Cheung, Dr.
-
New York、New York、美国、14621
- 招聘中
- Rochester General Hospital
-
接触:
- Dmitry Chuprun, MD
-
首席研究员:
- Dmitry Chuprun, MD
-
Syracuse、New York、美国、13057
- 招聘中
- SUNY-Upstate Medical University
-
接触:
- Jorge Romero, MD
-
首席研究员:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- 招聘中
- Sanger Heart and Vascular Institute
-
接触:
- Navid Nafissi, MD
-
首席研究员:
- Navid Nafissi, MD
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
接触:
- Daniel Friedman, MD
-
首席研究员:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus、Ohio、美国、43219
- 招聘中
- Mount Carmel Health System
-
接触:
- Kamel Addo, MD
-
首席研究员:
- Kamel Addo, MD
-
Columbus、Ohio、美国、43214
- 招聘中
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
接触:
- Anish Amin, MD
-
首席研究员:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Penn Presbyterian Medical Center
-
接触:
- John Bullinga, MD
-
首席研究员:
- John Bullinga, MD
-
Wilkes-Barre、Pennsylvania、美国、18702
- 招聘中
- Geisinger Wyoming Valley
-
首席研究员:
- Pugazhendhi Vijayaraman, MD
-
接触:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57108
- 招聘中
- Avera Heart Hospital of South Dakota
-
接触:
- Christopher Stanton, Dr.
-
首席研究员:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville、Tennessee、美国、37205
- 招聘中
- St.Thomas Health
-
接触:
- Ricardo Lugo, MD
-
首席研究员:
- Ricardo Lugo, MD
-
-
Texas
-
Plano、Texas、美国、75093
- 招聘中
- Heart Hospital Baylor Plano
-
接触:
- Mustafa Dohadwala, MD
-
首席研究员:
- Mustafa Dohadwala, MD
-
Tyler、Texas、美国、75701
- 招聘中
- Christus Trinity Mother Frances Health System
-
接触:
- Stanislov Weiner, Dr.
-
首席研究员:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- University of Virginia Medical Center
-
首席研究员:
- Pamela Mason, MD
-
接触:
- Pamela Mason, MD
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
有源比较器:CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
实验性的:LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
大体时间:Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
大体时间:12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Win ratio composite assessment
大体时间:Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
大体时间:Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
大体时间:12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.